Hosted on MSN17h
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon
Fact checked by Nick Blackmer Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne ...
Biogen lays out three FDA decisions that could ramp up Alzheimers drug launch
Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...
Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Daily Independent13h
With severe dementia, medications are of limited benefit
The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...
PMLiVE1h
Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...
Dementia risk may be twice as high as Americans live longer, study finds
Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in ...
Benzinga.com1d
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...
Common sleep medication may prevent brain from clearing 'waste'
In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively ...
Molecule shown to produce cognitive improvement in rodents with early Alzheimer's disease
A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...